Moderna’s stock tumbles after a disappointing outlook for revenue and the need to accelerate its cost-cutting plan.

"The S&P 500 is a different animal than in prior cycles," Bank of America's Savita Subramanian said in a note Friday.

The first few earnings reports from S&P 500 firms have already started to trickle in. But the fourth-quarter earnings ...

“However, rates should stay at higher levels relative to the pre-Covid era,” he says ... says he believes the stock market will ultimately post a positive return in 2024 as investors ...

According to S&P Global Market Intelligence, 20 of the 48 analysts covering the Magnificent 7 stock that it tracks rate TSLA ...

Intel revenues dropped from $79 billion in 2021 to $54 billion in 2023 as CPU sales declined due to the cooling off of the PC market post-Covid-19 and ... an individual stock, consider the High ...

On January 3, the Indian stock market fell significantly. Meanwhile, in China, the COVID-like HMPV virus is wreaking havoc, ...

He reiterated his in line rating on the stock and his $60 price target. Separately, Moderna said it has filed for approval of its next-generation COVID-19 vaccine and has filed for approval of its ...